Literature DB >> 11955452

XPD mutations prevent TFIIH-dependent transactivation by nuclear receptors and phosphorylation of RARalpha.

Anne Keriel1, Anne Stary, Alain Sarasin, Cécile Rochette-Egly, Jean Marc Egly.   

Abstract

Inherited mutations in the XPD subunit of the general transcription/repair factor TFIIH yield the rare genetic disorder Xeroderma pigmentosum (XP), the phenotypes of which cannot be explained solely on the basis of a DNA repair defect. In cells derived from XP-D patients, we observed a reduction of the ligand-dependent transactivation mediated by several nuclear receptors (RARalpha, ERalpha, and AR). We demonstrate that the XPD mutation alters cdk7 function in RARalpha phosphorylation. Transactivation is restored upon overexpression of either the wild-type XPD or the RARalphaS77E (a mutation which mimics phosphorylated RARalpha). Thus, we demonstrate that the cdk7 kinase of TFIIH phosphorylates the nuclear receptor, then allowing ligand-dependent control of the activation of the hormone-responsive genes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11955452     DOI: 10.1016/s0092-8674(02)00692-x

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  61 in total

1.  Phosphorylation by p38MAPK and recruitment of SUG-1 are required for RA-induced RAR gamma degradation and transactivation.

Authors:  Maurizio Giannì; Annie Bauer; Enrico Garattini; Pierre Chambon; Cécile Rochette-Egly
Journal:  EMBO J       Date:  2002-07-15       Impact factor: 11.598

2.  Phosphorylation of XPB helicase regulates TFIIH nucleotide excision repair activity.

Authors:  Frédéric Coin; Jérome Auriol; Angel Tapias; Pascale Clivio; Wim Vermeulen; Jean-Marc Egly
Journal:  EMBO J       Date:  2004-11-18       Impact factor: 11.598

3.  PPARγ and NF-κB regulate the gene promoter activity of their shared repressor, TNIP1.

Authors:  Igor Gurevich; Carmen Zhang; Priscilla C Encarnacao; Charles P Struzynski; Sarah E Livings; Brian J Aneskievich
Journal:  Biochim Biophys Acta       Date:  2011-10-07

4.  Transcription-associated breaks in xeroderma pigmentosum group D cells from patients with combined features of xeroderma pigmentosum and Cockayne syndrome.

Authors:  Therina Theron; Maria I Fousteri; Marcel Volker; Lorna W Harries; Elena Botta; Miria Stefanini; Mitsuo Fujimoto; Jaan-Olle Andressoo; Jay Mitchell; Nicolaas G J Jaspers; Lisa D McDaniel; Leon H Mullenders; Alan R Lehmann
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

5.  Increased apoptosis, p53 up-regulation, and cerebellar neuronal degeneration in repair-deficient Cockayne syndrome mice.

Authors:  R R Laposa; E J Huang; J E Cleaver
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-17       Impact factor: 11.205

Review 6.  Hot topics in DNA repair: the molecular basis for different disease states caused by mutations in TFIIH and XPG.

Authors:  Orlando D Schärer
Journal:  DNA Repair (Amst)       Date:  2008-02-01

Review 7.  TFIIH: when transcription met DNA repair.

Authors:  Emmanuel Compe; Jean-Marc Egly
Journal:  Nat Rev Mol Cell Biol       Date:  2012-05-10       Impact factor: 94.444

8.  ARCH domain of XPD, an anchoring platform for CAK that conditions TFIIH DNA repair and transcription activities.

Authors:  Wassim Abdulrahman; Izarn Iltis; Laura Radu; Cathy Braun; Anne Maglott-Roth; Christophe Giraudon; Jean-Marc Egly; Arnaud Poterszman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

9.  A coordinated phosphorylation cascade initiated by p38MAPK/MSK1 directs RARalpha to target promoters.

Authors:  Nathalie Bruck; Dominique Vitoux; Christine Ferry; Vanessa Duong; Annie Bauer; Hughes de Thé; Cécile Rochette-Egly
Journal:  EMBO J       Date:  2008-12-11       Impact factor: 11.598

10.  Mat1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipocyte differentiation.

Authors:  Katja Helenius; Ying Yang; Jukka Alasaari; Tomi P Mäkelä
Journal:  Mol Cell Biol       Date:  2008-11-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.